Active ingredientTovorafenibCat. No. P-T170-001CAS 1096708-71-2Family · Pharmaceutical analytical standards
Tovorafenib
An oral type II RAF kinase inhibitor, approved in the United States in April 2024 for relapsed or refractory paediatric low-grade glioma with BRAF alterations, from six months of age. This family brings together the active ingredient.
Did you know?According to the FDA it was the first systemic therapy approved for paediatric low-grade glioma with BRAF rearrangements; the approval was based on the FIREFLY-1 trial, with 76 participants.
Go to the active ingredient →Active ingredientTovorafenibCat. No. P-T170-001CAS 1096708-71-2No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.